Dr. Erik Eriksen
Dr. Eriksen has more than 20 years of experience in the bone health field with specialty in osteoporosis and calcium metabolic research. Dr. Eriksen is a professor of Endocrinology at Oslo University Hospital. He has served as the Global Product Medical Director at Novartis Pharmaceuticals, the Global Medical Director at Eli Lilly & Co., the Department Head of the Department of Endocrinology and Internal Medicine at Aarhus Amtssygehus, and an Associate Professor at University of Aarhus.
Dr. Eriksen has successfully taken two osteoporosis drugs (Forsteo and Aclasta) from clinical development to global launch. He has been awarded the Best Pharmaceutical Development team worldwide by Good Clinical Practice Journal, the Quality Prize for best Clinical Department in Århus Amt, and the Young Investigator Award by the American Society for Bone and Mineral Research.